Nautilus Biotechnology Q1 loss narrows to $14.7M; cash $143.4M

Nautilus Biotechnology, Inc.

2026-Q1 EPS reported -$0.12

Net loss of $14.7M vs $16.6M in Q1 2025; operating expenses down 14% YoY to $16.1M.
Cash, equivalents, and investments total $143.4M as of March 31, 2026.
Launched Iterative Mapping Early Access Program; Baylor College of Medicine first customer for Tau proteoform assay in NIH-funded cancer study.
Appointed Amber Faust as VP of Global Sales, a commercial leader from Olink and SomaLogic.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Nautilus Biotechnology, Inc. reported the quarter ended March 31, 2026 results: net income $14.7 million.

Period: the quarter ended March 31, 2026
Net income: $14.7 million
Result: reported results

Exact text from the filing

Net loss was $14.7 million for the first quarter of 2026

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

Nautilus Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001808805-26-000015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.